In this systematic review and meta-analysis, we synthesize the current evidence from RCTs to provide a comprehensive evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in the treatment of unresectable HCC (14, 15). Here, CD274 is linked to hepatocellular carcinoma.